PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+11.69%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$3.38B
AUM Growth
+$3.38B
(-2.6%)
Cap. Flow
+$174M
Cap. Flow
% of AUM
5.16%
Top 10 Holdings %
Top 10 Hldgs %
46.51%
Holding
114
New
18
Increased
20
Reduced
21
Closed
14
Top Buys
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$197M |
| 2 |
Orchestra BioMed
OBIO
|
$44.6M |
| 3 |
Sanofi
SNY
|
$41.8M |
| 4 |
Arcellx
ACLX
|
$38.3M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$36.6M |
Top Sells
Sector Composition
| 1 | Healthcare | 99.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Amicus Therapeutics
FOLD
$2.34B
| $307M | 9.06% | 27,662,917 +20,000 | +0.1% | +$222K |
|
|
RETA
2
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $197M | 5.82% | +2,169,276 | New | +$197M |
|
3
Amylyx Pharmaceuticals
AMLX
$836M
| $177M | 5.23% | 6,034,644 -53,689 | -0.9% | -$1.58M |
|
|
CERE
4
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $159M | 4.69% | 6,511,727 | – | – |
|
5
Madrigal Pharmaceuticals
MDGL
$9.76B
| $158M | 4.65% | 650,562 -81,370 | -11% | -$19.7M |
|
|
RXDX
6
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $137M | 4.03% | 1,272,694 +60,000 | +5% | +$6.44M |
|
|
7
Arcellx
ACLX
$3.85B
| $118M | 3.49% | 3,841,739 +1,243,434 | +48% | +$38.3M |
|
|
LIAN
8
DELISTED
LianBio American Depositary Shares
LIAN
| $113M | 3.33% | 57,558,451 | – | – |
|
9
Aldeyra Therapeutics
ALDX
$351M
| $113M | 3.33% | 11,350,085 | – | – |
|
10
Iovance Biotherapeutics
IOVA
$807M
| $93.7M | 2.77% | 15,339,735 +5,367,955 | +54% | +$32.8M |
|
|
INBX
11
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $68.2M | 2.01% | 3,615,383 +301,600 | +9% | +$5.69M |
|
12
Xenon Pharmaceuticals
XENE
$2.98B
| $65.6M | 1.94% | 1,832,174 -89,099 | -5% | -$3.19M |
|
13
BioMarin Pharmaceuticals
BMRN
$11.2B
| $65.4M | 1.93% | 673,060 +166,579 | +33% | +$16.2M |
|
14
Treace Medical Concepts
TMCI
$464M
| $61.5M | 1.82% | 2,442,250 +495,847 | +25% | +$12.5M |
|
15
Nuvalent
NUVL
$5.52B
| $60M | 1.77% | 2,300,048 +45,041 | +2% | +$1.18M |
|
|
MRTX
16
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $58.5M | 1.73% | 1,574,134 -617,291 | -28% | -$23M |
|
17
Crinetics Pharmaceuticals
CRNX
$2.92B
| $57.1M | 1.69% | 3,554,887 -484,389 | -12% | -$7.78M |
|
|
VRNA
18
Verona Pharma
VRNA
$9.16B
| $54.9M | 1.62% | 2,733,790 -2,146,929 | -44% | -$43.1M |
|
|
SWTX
19
DELISTED
SpringWorks Therapeutics
SWTX
| $53.5M | 1.58% | 2,079,352 -538,339 | -21% | -$13.9M |
|
|
20
Orchestra BioMed
OBIO
$147M
| $44.6M | 1.32% | +2,278,226 | New | +$44.6M |
|
21
Viridian Therapeutics
VRDN
$1.5B
| $44.2M | 1.3% | 1,736,386 +515,811 | +42% | +$13.1M |
|
22
Vaxcyte
PCVX
$4B
| $43.9M | 1.29% | 1,170,000 | – | – |
|
23
RAPT Therapeutics
RAPT
$188M
| $42.1M | 1.24% | 2,291,608 +492,653 | +27% | +$9.04M |
|
|
24
Sanofi
SNY
$121B
| $41.8M | 1.23% | +768,101 | New | +$41.8M |
|
25
ADMA Biologics
ADMA
$4.12B
| $39.4M | 1.16% | 11,900,255 | – | – |
|